Lu-177 PSMA vs Comparator Treatments and Survival in Metastatic Castration-Resistant Prostate Cancer
Open Access
- 3 September 2024
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (9) , e2433863
Abstract
Prostate-specific membrane antigen (PSMA) is a cell surface membrane protein highly expressed on prostate cancer cells.1,2 Lutetium Lu 177 vipivotide tetraxetan (Lu-177) PSMA was approved by the US Food and Drug Administration March 23, 2022, for the treatment of PSMA-positive, metastatic castration-resistant prostate cancer (mCRPC) previously treated with an androgen receptor pathway inhibitor and taxane-based chemotherapy.3 Lu-177 PSMA, consisting of a beta particle emitter that is linked to a PSMA-binding ligand, selectively binds to PSMA and delivers high doses of radiation to prostate cancer cells, causing their death.4-7Keywords
This publication has 19 references indexed in Scilit:
- Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trialThe Lancet Oncology, 2023
- PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trialThe Lancet Oncology, 2022
- Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate CancerNew England Journal of Medicine, 2021
- [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trialThe Lancet, 2021
- Adjusting for Treatment Switching in Oncology Trials: A Systematic Review and Recommendations for ReportingValue in Health, 2020
- Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate CancerNew England Journal of Medicine, 2019
- [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 studyThe Lancet Oncology, 2018
- Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical ApplicationsChemical Reviews, 2015
- Adjusting overall survival for treatment switches: commonly used methods and practical applicationPharmaceutical Statistics, 2013
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialThe Lancet, 2010